Adiponectin deficiency suppresses lymphoma growth in mice by modulating NK cells, CD8 T cells, and myeloid-derived suppressor cells

Journal of Immunology

Volumn 190, Issue 9, 2013, Pages 4877-4886

  Han, Sora ^a   Jeong, Ae Lee ^a   Lee, Sunyi ^a   Park, Jeong Su ^a   Kim, Kwang Dong ^b   Choi, Inpyo ^c   Yoon, Suk Ran ^c   Lee, Myung Sok ^a   Lim, Jong Seok ^a   Han, Seung Hyun ^d   Yoon, Do Young ^e   Yang, Young ^a  

^a Sookmyung Women's University   (South Korea)

^b Gyeongsang National University   (South Korea)

^c Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^d Seoul National University   (South Korea)

^e Konkuk University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER REGRESSION; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; DOWN REGULATION; IMMUNOMODULATION; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MALE; MELANOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SUPPRESSOR CELL; TUMOR IMMUNITY; UPREGULATION;

ADIPONECTIN; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; GENES, MHC CLASS I; GRANULOCYTE COLONY-STIMULATING FACTOR; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOMA; MALE; MELANOMA, EXPERIMENTAL; METABOLISM, INBORN ERRORS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID CELLS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY A; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84876795603     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1202487     Document Type: Article

References (47)

1. Miyoshi, Y., T. Funahashi, S. Kihara, T. Taguchi, Y. Tamaki, Y. Matsuzawa, and S. Noguchi. 2003. Association of serum adiponectin levels with breast cancer risk. Clin. Cancer Res. 9: 5699-5704. (Pubitemid 37499493)
2. Petridou, E., C. Mantzoros, N. Dessypris, P. Koukoulomatis, C. Addy, Z. Voulgaris, G. Chrousos, and D. Trichopoulos. 2003. Plasma adiponectin concentrations in relation to endometrial cancer: a case-control study in Greece. J. Clin. Endocrinol. Metab. 88: 993-997. (Pubitemid 36337745)
3. Ishikawa, M., J. Kitayama, S. Kazama, T. Hiramatsu, K. Hatano, and H. Nagawa. 2005. Plasma adiponectin and gastric cancer. Clin. Cancer Res. 11: 466-472. (Pubitemid 40116868)
4. Otake, S., H. Takeda, Y. Suzuki, T. Fukui, S. Watanabe, K. Ishihama, T. Saito, H. Togashi, T. Nakamura, Y. Matsuzawa, and S. Kawata. 2005. Association of visceral fat accumulation and plasma adiponectin with colorectal adenoma: evidence for participation of insulin resistance. Clin. Cancer Res. 11: 3642-3646. (Pubitemid 40685579)
5. Goktas, S., M. I. Yilmaz, K. Caglar, A. Sonmez, S. Kilic, and S. Bedir. 2005. Prostate cancer and adiponectin. Urology 65: 1168-1172. (Pubitemid 40824911)
6. Avcu, F., A. U. Ural, M. I. Yilmaz, N. Bingol, O. Nevruz, and K. Caglar. 2006. Association of plasma adiponectin concentrations with chronic lymphocytic leukemia and myeloproliferative diseases. Int. J. Hematol. 83: 254-258. (Pubitemid 44228002)
7. Denzel, M. S., L. W. Hebbard, G. Shostak, L. Shapiro, R. D. Cardiff, and B. Ranscht. 2009. Adiponectin deficiency limits tumor vascularization in the MMTV-PyV-mT mouse model of mammary cancer. Clin. Cancer Res. 15: 3256-3264.
8. Lam, J. B., K. H. Chow, A. Xu, K. S. Lam, J. Liu, N. S. Wong, R. T. Moon, P. R. Shepherd, G. J. Cooper, and Y. Wang. 2009. Adiponectin haploinsufficiency promotes mammary tumor development in MMTV-PyVT mice by modulation of phosphatase and tensin homolog activities. PLoS ONE 4: e4968.
9. Landskroner-Eiger, S., B. Qian, E. S. Muise, A. R. Nawrocki, J. P. Berger, E. J. Fine, W. Koba, Y. Deng, J. W. Pollard, and P. E. Scherer. 2009. Proan-giogenic contribution of adiponectin toward mammary tumor growth in vivo. Clin. Cancer Res. 15: 3265-3276.
10. Sun, Y., and H. F. Lodish. 2010. Adiponectin deficiency promotes tumor growth in mice by reducing macrophage infiltration. PLoS ONE 5: e11987.
11. Fayad, R., M. Pini, J. A. Sennello, R. J. Cabay, L. Chan, A. Xu, and G. Fantuzzi. 2007. Adiponectin deficiency protects mice from chemically induced colonic inflammation. Gastroenterology 132: 601-614. (Pubitemid 46274660)
12. Kobashi, C., M. Urakaze, M. Kishida, E. Kibayashi, H. Kobayashi, S. Kihara, T. Funahashi, M. Takata, R. Temaru, A. Sato, et al. 2005. Adiponectin inhibits endothelial synthesis of interleukin-8. Circ. Res. 97: 1245-1252.
13. Saxena, A., A. Chumanevich, E. Fletcher, B. Larsen, K. Lattwein, K. Kaur, and R. Fayad. 2012. Adiponectin deficiency: role in chronic inflammation induced colon cancer. Biochim. Biophys. Acta 1822: 527-536.
14. Pamuk, G. E., B. Turgut, M. Demir, and O. Vural. 2006. Increased adiponectin level in non-Hodgkin lymphoma and its relationship with interleukin-10: correlation with clinical features and outcome. J. Exp. Clin. Cancer Res. 25: 537-541. (Pubitemid 46166768)
15. Petridou, E. T., N. Dessypris, P. Panagopoulou, T. N. Sergentanis, A. F. Mentis, A. Pourtsidis, S. Polychronopoulou, M. Kalmanti, F. Athanasiadou- Piperopoulou, and M. Moschovi. 2010. Adipocytokines in relation to Hodgkin lymphoma in children. Pediatr. Blood Cancer 54: 311-315.
16. Petridou, E. T., T. N. Sergentanis, N. Dessypris, I. T. Vlachantoni, S. Tseleni-Balafouta, A. Pourtsidis, M. Moschovi, S. Polychronopoulou, F. Athanasiadou-Piperopoulou, M. Kalmanti, and C. S. Mantzoros. 2009. Serum adiponectin as a predictor of childhood non-Hodgkin's lymphoma: a nationwide case-control study. J. Clin. Oncol. 27: 5049-5055.
17. Petridou, E., C. S. Mantzoros, N. Dessypris, S. K. Dikalioti, and D. Trichopoulos. 2006. Adiponectin in relation to childhood myeloblastic leukaemia. Br. J. Cancer 94: 156-160. (Pubitemid 43088557)
18. Kim, K. Y., J. K. Kim, S. H. Han, J. S. Lim, K. I. Kim, D. H. Cho, M. S. Lee, J. H. Lee, D. Y. Yoon, S. R. Yoon, et al. 2006. Adiponectin is a negative regulator of NK cell cytotoxicity. J. Immunol. 176: 5958-5964.
19. Chung, J. W., M. S. Kim, Z. H. Piao, M. Jeong, S. R. Yoon, N. Shin, S. Y. Kim, E. S. Hwang, Y. Yang, Y. H. Lee, et al. 2008. Osteopontin promotes the de velopment of natural killer cells from hematopoietic stem cells. Stem Cells 26: 2114-2123.
20. Esplugues, E., D. Sancho, J. Vega-Ramos, C. Martínez, U. Syrbe, A. Hamann, P. Engel, F. Sánchez-Madrid, and P. Lauzurica. 2003. Enhanced antitumor immunity in mice deficient in CD69. J. Exp. Med. 197: 1093-1106. (Pubitemid 36570065)
21. Lee, K. N., H. S. Kang, J. H. Jeon, E. M. Kim, S. R. Yoon, H. Song, C. Y. Lyu, Z. H. Piao, S. U. Kim, Y. H. Han, et al. 2005. VDUP1 is required for the development of natural killer cells. Immunity 22: 195-208. (Pubitemid 40255711)
22. Kim, K. Y., A. Baek, J. E. Hwang, Y. A. Choi, J. Jeong, M. S. Lee, D. H. Cho, J. S. Lim, K. I. Kim, and Y. Yang. 2009. Adiponectin-activated AMPK stimulates dephosphorylation of AKT through protein phosphatase 2A activation. Cancer Res. 69: 4018-4026.
23. Suttles, J., G. A. Schwarting, and R. D. Stout. 1986. Flow cytometric analysis reveals the presence of asialo GM1 on the surface membrane of alloimmune cytotoxic T lymphocytes. J. Immunol. 136: 1586-1591. (Pubitemid 16119560)
24. DiMascio, L., C. Voermans, M. Uqoezwa, A. Duncan, D. Lu, J. Wu, U. Sankar, and T. Reya. 2007. Identification of adiponectin as a novel hemopoietic stem cell growth factor. J. Immunol. 178: 3511-3520. (Pubitemid 46417616)
25. Gabrilovich, D. I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9: 162-174.
26. Lanier, L. L. 2005. NK cell recognition. Annu. Rev. Immunol. 23: 225-274. (Pubitemid 40563170)
27. Nakamura, M. C., E. C. Niemi, M. J. Fisher, L. D. Shultz, W. E. Seaman, and J. C. Ryan. 1997. Mouse Ly-49A interrupts early signaling events in natural killer cell cytotoxicity and functionally associates with the SHP-1 tyrosine phosphatase. J. Exp. Med. 185: 673-684. (Pubitemid 27098152)
28. Mason, L. H., P. Gosselin, S. K. Anderson, W. E. Fogler, J. R. Ortaldo, and D. W. McVicar. 1997. Differential tyrosine phosphorylation of inhibitory versus activating Ly-49 receptor proteins and their recruitment of SHP-1 phosphatase. J. Immunol. 159: 4187-4196. (Pubitemid 127470573)
29. Mason, L. H., S. K. Anderson, W. M. Yokoyama, H. R. Smith, R. Winkler-Pickett, and J. R. Ortaldo. 1996. The Ly-49D receptor activates murine natural killer cells. J. Exp. Med. 184: 2119-2128. (Pubitemid 27023713)
30. George, T. C., L. H. Mason, J. R. Ortaldo, V. Kumar, and M. Bennett. 1999. Positive recognition of MHC class I molecules by the Ly49D receptor of murine NK cells. J. Immunol. 162: 2035-2043. (Pubitemid 29288822)
31. Ortaldo, J. R., and H. A. Young. 2003. Expression of IFN-g upon triggering of activating Ly49D NK receptors in vitro and in vivo: costimulation with IL-12 or IL-18 overrides inhibitory receptors. J. Immunol. 170: 1763-1769. (Pubitemid 36197391)
32. Kato, Y., Y. Tanaka, F. Miyagawa, S. Yamashita, and N. Minato. 2001. Targeting of tumor cells for human gammadelta T cells by nonpeptide antigens. J. Immunol. 167: 5092-5098. (Pubitemid 33009743)
33. Sasiain, M. C., S. de la Barrera, S. Fink, M. Finiasz, M. Alemán, M. H. Fariña, G. Pizzariello, and R. Valdez. 1998. Interferon-g (IFN-g) and tumour necrosis factor-a (TNF-a) are necessary in the early stages of induction of CD4 and CD8 cytotoxic T cells by Mycobacterium leprae heat shock protein (hsp) 65 kD. Clin. Exp. Immunol. 114: 196-203. (Pubitemid 28505718)
34. Erdag, G., J. T. Schaefer, M. E. Smolkin, D. H. Deacon, S. M. Shea, L. T. Dengel, J. W. Patterson, and C. L. Slingluff, Jr. 2012. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res. 72: 1070-1080.
35. Kurosawa, S., M. Harada, G. Matsuzaki, Y. Shinomiya, H. Terao, N. Kobayashi, and K. Nomoto. 1995. Early-appearing tumour-infiltrating natural killer cells play a crucial role in the generation of anti-tumour T lymphocytes. Immunology 85: 338-346.
36. Merck, E., R. B. Voyle, and H. R. MacDonald. 2009. Ly49D engagement on T lymphocytes induces TCR-independent activation and CD8 effector functions that control tumor growth. J. Immunol. 182: 183-192.
37. Tanikawa, T., C. M. Wilke, I. Kryczek, G. Y. Chen, J. Kao, G. Núñez, and W. Zou. 2012. Interleukin-10 ablation promotes tumor development, growth, and metastasis. Cancer Res. 72: 420-429.
38. Hart, K. M., K. T. Byrne, M. J. Molloy, E. M. Usherwood, and B. Berwin. 2011. IL-10 immunomodulation of myeloid cells regulates a murine model of ovarian cancer. Front. Immunol. 2: 29.
39. Capuano, G., N. Rigamonti, M. Grioni, M. Freschi, and M. Bellone. 2009. Modulators of arginine metabolism support cancer immunosurveillance. BMC Immunol. 10: 1.
40. Fujimoto, A., S. Akifusa, T. Hirofuji, and Y. Yamashita. 2011. Involvement of suppressor of cytokine signaling-1 in globular adiponectin-induced granulocyte colony-stimulating factor in RAW 264 cell. Mol. Immunol. 48: 2052-2058.
41. Kamio, N., S. Akifusa, N. Yamaguchi, and Y. Yamashita. 2008. Induction of granulocyte colony-stimulating factor by globular adiponectin via the MEK-ERK pathway. Mol. Cell. Endocrinol. 292: 20-25.
42. Visseren, M. J., M. Koot, E. I. van der Voort, L. A. Gravestein, H. J. Schoenmakers, W. M. Kast, M. Zijlstra, and C. J. Melief. 1994. Production of interleukin-2 by EL4 tumor cells induces natural killer cell-and T-cell-mediated immunity. J. Immunother. Emphasis Tumor Immunol. 15: 119-128. (Pubitemid 24047544)
43. Ashley, M. P., and I. Kotlarski. 1987. In vivo H-2K and H-2D antigen expression in two allogeneic mouse tumours of low immunogenicity. Immunol. Cell Biol. 65: 323-328.
44. Brocker, T., M. Riedinger, and K. Karjalainen. 1997. Targeted expression of major histocompatibility complex (MHC) class II molecules demonstrates that dendritic cells can induce negative but not positive selection of thymocytes in vivo. J. Exp. Med. 185: 541-550. (Pubitemid 27078372)
45. Wilk, S., C. Scheibenbogen, S. Bauer, A. Jenke, M. Rother, M. Guerreiro, R. Kudernatsch, N. Goerner, W. Poller, D. Elligsen-Merkel, et al. 2011. Adi-ponectin is a negative regulator of antigen-activated T cells. Eur. J. Immunol. 41: 2323-2332.
46. Sugiyama, M., H. Takahashi, K. Hosono, H. Endo, S. Kato, K. Yoneda, Y. Nozaki, K. Fujita, M. Yoneda, K. Wada, et al. 2009. Adiponectin inhibits colorectal cancer cell growth through the AMPK/mTOR pathway. Int. J. Oncol. 34: 339-344.
47. Arditi, J. D., M. Venihaki, K. P. Karalis, and G. P. Chrousos. 2007. Anti-proliferative effect of adiponectin on MCF7 breast cancer cells: a potential hormonal link between obesity and cancer. Horm. Metab. Res. 39: 9-13. (Pubitemid 46535150)